Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study
Journal article published in 2010 by
Joel Kremer,
Christopher Ritchlin 
,
Alan Mendelsohn,
Daniel Baker,
Lilianne Kim,
Zhenhua Xu,
John Han,
Peter Taylor
,
Alan Mendelsohn,
Daniel Baker,
Lilianne Kim,
Zhenhua Xu,
John Han,
Peter Taylor
Abstract
OBJECTIVE: To assess the efficacy and safety of intravenous administration of golimumab in patients with rheumatoid arthritis (RA). METHODS: Adult patients with RA in whom disease activity was persistent despite treatment with methotrexate (MTX) at a dosage of 15-25 mg/week for > or = 4 weeks were randomized to receive intravenous infusions of placebo plus MTX or intravenous infusions of golimumab at a dose of 2 mg/kg or 4 mg/kg, with or without MTX, every 12 weeks through week 48. Patients with